Key result
Long-term administration of EPA significantly reduced 28-day postinfarct mortality to 41.2% compared to 59.3% with PBS in a mouse model of myocardial infarction.
Why the study?
Does eicosapentaenoic acid (EPA) reduce postinfarct mortality and improve cardiac remodeling in a mouse model of myocardial infarction?
Does eicosapentaenoic acid (EPA) reduce postinfarct mortality and improve cardiac remodeling in a mouse model of myocardial infarction?
Long-term EPA administration reduces post-MI mortality and attenuates maladaptive cardiac remodeling in mice by inhibiting the polarization of proinflammatory M1 macrophages.
BACKGROUND: Consumption of n-3 fatty acids reduces the incidence of cardiovascular mortality in populations that consume diets rich in fish oil. Eicosapentaenoic acid (EPA) is an n-3 fatty acid known to reduce the frequency of nonfatal coronary events; however, the frequency of mortality after myocardial infarction (MI) is not reduced. The aims of this study were to determine whether long-term administration of EPA regulated cardiac remodeling after MI and to elucidate the underlying therapeutic mechanisms of EPA. METHODS AND RESULTS: C57BL/6J mice were divided into control (phosphate-buffered saline-treated) and EPA-treated groups. After 28 days of treatment, the mice were subjected to either sham surgery or MI by left anterior descending coronary artery ligation. Mortality due to MI or heart failure was significantly lower in the EPA-treated mice than in the phosphate-buffered saline-treated mice. However, the incidence of cardiac rupture was comparable between the EPA-treated mice and the phosphate-buffered saline-treated mice after MI. Echocardiographic tests indicated that EPA treatment attenuated post-MI cardiac remodeling by preventing issues such as left ventricular systolic dysfunction and left ventricle dilatation 28 days after MI induction. Moreover, during the chronic remodeling phase, ie, 28 days after MI, flow cytometry demonstrated that EPA treatment significantly inhibited polarization toward proinflammatory M1 macrophages, but not anti-inflammatory M2 macrophages, in the infarcted heart. Furthermore, EPA treatment attenuated fibrosis in the noninfarcted remote areas during the chronic phase. CONCLUSIONS: Long-term administration of EPA improved the prognosis of and attenuated chronic cardiac remodeling after MI by modulating the activation of proinflammatory M1 macrophages.
No takes yet. Share an insight, caveat, or question.
Takamura et al. (2017) studied Myocardial Infarction (Preclinical Model) (n=216). Eicosapentaenoic acid (EPA) vs. Phosphate-buffered saline (PBS) was evaluated on Postinfarct mortality at 28 days (p=0.0361). Long-term administration of EPA significantly reduced 28-day postinfarct mortality to 41.2% compared to 59.3% with PBS in a mouse model of myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: